Is AQST or PLYX more profitable?

Polaryx Therapeutics has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -137.08%. Company Net Margins Return on Equity Return on Assets Aquestive Therapeutics -137.08% N/A -49.33% Polaryx Therapeutics N/A N/A N/A

Which has stronger valuation & earnings, CABA or PLYX?

Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cabaletta Bio N/A N/A -$167.86M -$1.96 N/A Polaryx Therapeutics N/A N/A N/A -$0.05 N/A

Is CABA or PLYX more profitable?

Polaryx Therapeutics' return on equity of 0.00% beat Cabaletta Bio's return on equity. Company Net Margins Return on Equity Return on Assets Cabaletta Bio N/A -131.58% -96.46% Polaryx Therapeutics N/A N/A N/A

Which has preferable valuation & earnings, PLYX or NVCT?

Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Nuvectis Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Polaryx Therapeutics N/A N/A N/A -$0.05 N/A Nuvectis Pharma N/A N/A -$26.44M -$1.31 N/A

Is PLYX or NVCT more profitable?

Polaryx Therapeutics' return on equity of 0.00% beat Nuvectis Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Polaryx Therapeutics N/A N/A N/A Nuvectis Pharma N/A -161.00% -98.88%

Is OCGN or PLYX more profitable?

Polaryx Therapeutics' return on equity of 0.00% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Ocugen N/A -127,987.80% -135.48% Polaryx Therapeutics N/A N/A N/A

Polaryx Therapeutics (PLYX) Competitors

$2.81 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$2.77 -0.04 (-1.42%)

As of 07/2/2026 07:56 PM Eastern

Compare

PLYX vs. AQST, CABA, NVCT, OCGN, and PRTA

Should you buy Polaryx Therapeutics stock or one of its competitors? MarketBeat compares Polaryx Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Polaryx Therapeutics include Aquestive Therapeutics (AQST), Cabaletta Bio (CABA), Nuvectis Pharma (NVCT), Ocugen (OCGN), and Prothena (PRTA). These companies are all part of the "pharmaceutical products" industry.

How does Polaryx Therapeutics compare to Aquestive Therapeutics?

Aquestive Therapeutics (NASDAQ:AQST) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, risk, analyst recommendations, earnings and institutional ownership.

In the previous week, Aquestive Therapeutics' average media sentiment score of 0.00 equaled Polaryx Therapeutics'average media sentiment score.

Company	Overall Sentiment
Aquestive Therapeutics	Neutral
Polaryx Therapeutics	Neutral

32.5% of Aquestive Therapeutics shares are held by institutional investors. 6.8% of Aquestive Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Polaryx Therapeutics has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -137.08%.

Company	Net Margins	Return on Equity	Return on Assets
Aquestive Therapeutics	-137.08%	N/A	-49.33%
Polaryx Therapeutics	N/A	N/A	N/A

Polaryx Therapeutics has lower revenue, but higher earnings than Aquestive Therapeutics. Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Aquestive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aquestive Therapeutics	$50.27M	10.43	-$83.78M	-$0.61	N/A
Polaryx Therapeutics	N/A	N/A	N/A	-$0.05	N/A

Aquestive Therapeutics presently has a consensus price target of $8.50, suggesting a potential upside of 103.35%. Polaryx Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 255.87%. Given Polaryx Therapeutics' higher probable upside, analysts plainly believe Polaryx Therapeutics is more favorable than Aquestive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Polaryx Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Aquestive Therapeutics beats Polaryx Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Polaryx Therapeutics compare to Cabaletta Bio?

Cabaletta Bio (NASDAQ:CABA) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends.

Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.96	N/A
Polaryx Therapeutics	N/A	N/A	N/A	-$0.05	N/A

Cabaletta Bio currently has a consensus price target of $15.50, indicating a potential upside of 385.89%. Polaryx Therapeutics has a consensus price target of $10.00, indicating a potential upside of 255.87%. Given Cabaletta Bio's stronger consensus rating and higher possible upside, equities analysts plainly believe Cabaletta Bio is more favorable than Polaryx Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Polaryx Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Cabaletta Bio's average media sentiment score of 0.00 equaled Polaryx Therapeutics'average media sentiment score.

Company	Overall Sentiment
Cabaletta Bio	Neutral
Polaryx Therapeutics	Neutral

Polaryx Therapeutics' return on equity of 0.00% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cabaletta Bio	N/A	-131.58%	-96.46%
Polaryx Therapeutics	N/A	N/A	N/A

Summary

Cabaletta Bio beats Polaryx Therapeutics on 4 of the 7 factors compared between the two stocks.

How does Polaryx Therapeutics compare to Nuvectis Pharma?

Polaryx Therapeutics (NASDAQ:PLYX) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability.

Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Nuvectis Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polaryx Therapeutics	N/A	N/A	N/A	-$0.05	N/A
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A

96.8% of Nuvectis Pharma shares are owned by institutional investors. 28.6% of Nuvectis Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Nuvectis Pharma had 11 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 11 mentions for Nuvectis Pharma and 0 mentions for Polaryx Therapeutics. Nuvectis Pharma's average media sentiment score of 0.86 beat Polaryx Therapeutics' score of 0.00 indicating that Nuvectis Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Polaryx Therapeutics	Neutral
Nuvectis Pharma	Positive

Polaryx Therapeutics presently has a consensus price target of $10.00, indicating a potential upside of 255.87%. Nuvectis Pharma has a consensus price target of $39.00, indicating a potential upside of 99.28%. Given Polaryx Therapeutics' higher possible upside, research analysts clearly believe Polaryx Therapeutics is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polaryx Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Polaryx Therapeutics' return on equity of 0.00% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polaryx Therapeutics	N/A	N/A	N/A
Nuvectis Pharma	N/A	-161.00%	-98.88%

Summary

Nuvectis Pharma beats Polaryx Therapeutics on 5 of the 9 factors compared between the two stocks.

How does Polaryx Therapeutics compare to Ocugen?

Ocugen (NASDAQ:OCGN) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Ocugen had 2 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 2 mentions for Ocugen and 0 mentions for Polaryx Therapeutics. Ocugen's average media sentiment score of 0.44 beat Polaryx Therapeutics' score of 0.00 indicating that Ocugen is being referred to more favorably in the media.

Company	Overall Sentiment
Ocugen	Neutral
Polaryx Therapeutics	Neutral

10.3% of Ocugen shares are owned by institutional investors. 4.0% of Ocugen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Ocugen currently has a consensus price target of $9.50, indicating a potential upside of 529.14%. Polaryx Therapeutics has a consensus price target of $10.00, indicating a potential upside of 255.87%. Given Ocugen's stronger consensus rating and higher probable upside, research analysts clearly believe Ocugen is more favorable than Polaryx Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Polaryx Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Polaryx Therapeutics' return on equity of 0.00% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocugen	N/A	-127,987.80%	-135.48%
Polaryx Therapeutics	N/A	N/A	N/A

Polaryx Therapeutics has lower revenue, but higher earnings than Ocugen. Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocugen	$4.41M	115.91	-$67.85M	-$0.24	N/A
Polaryx Therapeutics	N/A	N/A	N/A	-$0.05	N/A

Summary

Ocugen beats Polaryx Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Polaryx Therapeutics compare to Prothena?

Prothena (NASDAQ:PRTA) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

Polaryx Therapeutics has lower revenue, but higher earnings than Prothena. Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prothena	$9.68M	52.40	-$244.09M	-$2.82	N/A
Polaryx Therapeutics	N/A	N/A	N/A	-$0.05	N/A

Polaryx Therapeutics has a net margin of 0.00% compared to Prothena's net margin of -260.92%. Polaryx Therapeutics' return on equity of 0.00% beat Prothena's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prothena	-260.92%	-43.44%	-36.87%
Polaryx Therapeutics	N/A	N/A	N/A

Prothena presently has a consensus target price of $23.75, suggesting a potential upside of 145.10%. Polaryx Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 255.87%. Given Polaryx Therapeutics' higher probable upside, analysts clearly believe Polaryx Therapeutics is more favorable than Prothena.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prothena	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Polaryx Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

97.1% of Prothena shares are held by institutional investors. 10.4% of Prothena shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Prothena had 1 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 1 mentions for Prothena and 0 mentions for Polaryx Therapeutics. Prothena's average media sentiment score of 0.00 equaled Polaryx Therapeutics'average media sentiment score.

Company	Overall Sentiment
Prothena	Neutral
Polaryx Therapeutics	Neutral

Summary

Prothena beats Polaryx Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Polaryx Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLYX vs. The Competition

Export

Metric	Polaryx Therapeutics	Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$132.15M	$3.14B	$5.20B	$12.48B
Dividend Yield	N/A	15.26%	16.11%	6.52%
P/E Ratio	-56.20	13.51	23.91	24.70
Price / Sales	N/A	2,827.48	217.06	99.46
Price / Cash	N/A	25.31	35.06	57.09
Price / Book	N/A	5.15	13.25	6.46
Net Income	N/A	-$34.63M	$113.80M	$337.01M
7 Day Performance	17.08%	1.00%	0.93%	1.69%
1 Month Performance	20.60%	0.85%	1.08%	3.81%
1 Year Performance	N/A	12.21%	10.03%	23.90%

Polaryx Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLYX Polaryx Therapeutics	2.0034 of 5 stars	$2.81 flat	$10.00 +255.9%	N/A	$132.15M	N/A	N/A	11	Analyst Upgrade
AQST Aquestive Therapeutics	2.4462 of 5 stars	$4.18 flat	$8.50 +103.3%	+12.4%	$524.45M	$44.54M	N/A	160
CABA Cabaletta Bio	1.9801 of 5 stars	$3.19 flat	$15.50 +385.9%	+98.6%	$520.15M	N/A	N/A	50	Gap Down
NVCT Nuvectis Pharma	3.7562 of 5 stars	$19.57 flat	$39.00 +99.3%	+154.2%	$519.10M	N/A	N/A	8	Insider Trade
OCGN Ocugen	2.2539 of 5 stars	$1.51 flat	$9.50 +529.1%	+56.3%	$511.17M	$4.41M	N/A	80	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PLYX) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Polaryx Therapeutics (PLYX) Competitors

PLYX vs. AQST, CABA, NVCT, OCGN, and PRTA

How does Polaryx Therapeutics compare to Aquestive Therapeutics?

Summary

How does Polaryx Therapeutics compare to Cabaletta Bio?

Summary

How does Polaryx Therapeutics compare to Nuvectis Pharma?

Summary

How does Polaryx Therapeutics compare to Ocugen?

Summary

How does Polaryx Therapeutics compare to Prothena?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLYX vs. The Competition

Polaryx Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Polaryx Therapeutics (PLYX) Competitors

PLYX vs. AQST, CABA, NVCT, OCGN, and PRTA

How does Polaryx Therapeutics compare to Aquestive Therapeutics?

Does the media favor AQST or PLYX?

Do institutionals & insiders hold more shares of AQST or PLYX?

Is AQST or PLYX more profitable?

Which has higher valuation and earnings, AQST or PLYX?

Do analysts recommend AQST or PLYX?

Summary

How does Polaryx Therapeutics compare to Cabaletta Bio?

Which has stronger valuation & earnings, CABA or PLYX?

Do analysts rate CABA or PLYX?

Does the media favor CABA or PLYX?

Is CABA or PLYX more profitable?

Summary

How does Polaryx Therapeutics compare to Nuvectis Pharma?

Which has preferable valuation & earnings, PLYX or NVCT?

Do insiders & institutionals believe in PLYX or NVCT?

Does the media refer more to PLYX or NVCT?

Do analysts recommend PLYX or NVCT?

Is PLYX or NVCT more profitable?

Summary

How does Polaryx Therapeutics compare to Ocugen?

Does the media prefer OCGN or PLYX?

Do institutionals & insiders believe in OCGN or PLYX?

Do analysts recommend OCGN or PLYX?

Is OCGN or PLYX more profitable?

Which has stronger earnings and valuation, OCGN or PLYX?

Summary

How does Polaryx Therapeutics compare to Prothena?

Which has higher valuation & earnings, PRTA or PLYX?

Is PRTA or PLYX more profitable?

Do analysts rate PRTA or PLYX?

Do institutionals & insiders have more ownership in PRTA or PLYX?

Does the media prefer PRTA or PLYX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLYX vs. The Competition

Polaryx Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools